WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances.
The order directs the Food and Drug Administration to expedite some psychedelics as break...
This executive order represents a dramatic shift in federal drug policy, leveraging anecdotal evidence and political advocacy to bypass traditional regulatory timelines. The strongest version of this narrative frames it as a bold, compassionate response to a mental health crisis, particularly for veterans, with Trump positioning himself as a disruptor of bureaucratic inertia. However, the pattern scan reveals potential concerns: the reliance on testimonials over rigorous data (ARC-0024 Ambiguity...